Production of novel camelid anti-CXCL10 specific polyclonal antibodies and evaluation of their bioreactivity

  • سال انتشار: 1397
  • محل انتشار: بیستمین کنگره ملی و هشتمین کنگره بین‌المللی زیست‌شناسی ایران
  • کد COI اختصاصی: BIOCONF20_197
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 436
دانلود فایل این مقاله

نویسندگان

Tahereh Sadeghian-Rizi

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences,Isfahan, Iran

Ali Jahanian-Najafabadi

Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences,Isfahan, Iran

Hossein Khanahmad

Department of Genetics and Molecular Biology, Isfahan University of Medical Science, Isfahan, Iran

Mahdi Behdani

Biotechnology Research Center, Medical Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

چکیده

CXCL10 is a member of the CXC chemokine family. It is secreted from a variety of cells in response to IFN-γ and stimulates a range of inflammatory responses via binding to its receptor, CXCR3. CXCL10 has a pivotal role in the pathogenesis of various infectious diseases, cancers, inflammatory and autoimmune diseases. It has been put forward as a potential biomarker and therapeutic target in diagnosis and treatment of these diseases. In the present study, production of camel heavy chain antibodies (HCAbs) specific to the CXCL10 is reported. In this regard, recombinant CXCL10 was used for immunization of camel and subsequently, the CXCL10 HCAbs were obtained. Afterward, three subclasses of IgG were separated using protein A and protein G affinity columns, characterized by SDS-PAGE and confirmed for specific binding to the CXCL10 using ELISA. These IgG subclasses successfully recognized CXCL10 and a strong and specific reactivity towards CXCL10 were observed. Therefore, the selected HCAbs and their corresponding expression library could be used to develop a recombinant variable domain of these HCAbs (nanobody or VHH) as a new possible strategy for treatment of multiple sclerosis and other autoimmune diseases.

کلیدواژه ها

CXCL10, Polyclonal antibody, Heavy chain antibody, Nanobody, Multiple sclerosis, Chemokine

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.